Published in Eur Heart J on September 29, 2015
Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. Eur Heart J (2015) 0.80
Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Sci Rep (2016) 0.77
Predicting Atrial Fibrillation and Its Complications. Circ J (2016) 0.77
Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project. Sci Rep (2016) 0.75
Atrial fibrillation in women: treatment. Nat Rev Cardiol (2016) 0.75
Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine (2016) 0.75
The 5-factor ORBIT bleeding score predicted major bleeding at 2 years in patients with atrial fibrillation. Ann Intern Med (2016) 0.75
Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. Int J Gen Med (2016) 0.75
Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. Thromb J (2016) 0.75
Perioperative management of patients on direct oral anticoagulants. Thromb J (2017) 0.75
Risks of postextraction bleeding after receiving direct oral anticoagulants or warfarin: a retrospective cohort study. BMJ Open (2017) 0.75
Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Sci Rep (2017) 0.75
Resumption of Anticoagulation After Intracranial Hemorrhage. Curr Treat Options Neurol (2017) 0.75
Association between subjective risk perception and objective risk estimation in patients with atrial fibrillation: a cross-sectional study. BMJ Open (2017) 0.75
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm (2017) 0.75
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost (2005) 5.92
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ (2001) 4.66
A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA (1999) 4.31
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22
Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology (2007) 2.16
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01
Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing (2011) 1.94
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ (2015) 1.81
Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med (2012) 1.81
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72
Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost (2013) 1.03
Methodologic problems in the assessment of bleed scores. J Am Coll Cardiol (2013) 1.01
Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2012) 1.00
Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol (2012) 0.93
Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol (2014) 0.85
Reply: To PMID 22575324. J Am Coll Cardiol (2012) 0.81
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J (2014) 1.12
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J (2014) 0.92
Impaired platelet nitric oxide response in patients with new onset atrial fibrillation. Int J Cardiol (2014) 0.89
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Untreated aortic valve stenosis identified at the time of coronary artery bypass grafting: thresholds associated with adverse prognosis. Eur J Cardiothorac Surg (2014) 0.76